The offering raised net proceeds of $6.2 million, which will be used for working capital and general corporate purposes, the firm said.
The results also suggest the cfDNA assay has high sensitivity and 100 percent specificity, comparable to other technologies being developed for liquid biopsy testing.
Tests in development for the Alere q include HIV, tuberculosis, and Ebola assays, and it will initially be targeted to low-resource settings in the developing world.
The Singapore-based molecular diagnostics firm continues to operate under court supervision while its finances get sorted out.
The firm, which went public in October, made a public offering of more than 2.5 million units at $8.80 per unit.
In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.
Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.
Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.
Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.